Expression and localization of FOXO1 in non-small cell lung cancer

Takayo Maekawa1, Yoshimasa Maniwa, Takefumi Doi

  • 1Division of Thoracic Surgery, International Center for Medical Research and Treatment, Kobe University Graduate School of Medicine, Kobe, Japan.

Oncology Reports
|June 11, 2009
PubMed

Insights

Forkhead box protein 1 (FOXO1) nuclear localization correlates with favorable prognosis in non-small cell lung cancer (NSCLC). Inhibition of Akt signaling promotes FOXO1 nuclear translocation and apoptosis, suggesting FOXO1 is a positive prognostic marker.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cell Biology

Background:

  • Forkhead box protein 1 (FOXO1) is a transcription factor implicated in apoptosis.
  • Akt signaling pathway regulates FOXO1 activity through phosphorylation and cytoplasmic sequestration.
  • Understanding FOXO1 localization is crucial for deciphering its role in non-small cell lung cancer (NSCLC).

Purpose of the Study:

  • To investigate the cellular localization of FOXO1 in NSCLC cell lines and clinical samples.
  • To determine the relationship between Akt activity, FOXO1 localization, and apoptosis in NSCLC.
  • To assess the prognostic significance of FOXO1 expression in NSCLC patients.

Main Methods:

  • Immunohistochemistry and immunofluorescence on NSCLC cell lines and 185 clinical tumor samples.
  • RNA interference to inhibit Akt signaling in NSCLC cell lines.
  • Analysis of FOXO1 expression, Akt activity, and apoptosis induction.

Main Results:

  • FOXO1 localized to the nucleus in the absence of fetal bovine serum (FBS) and translocated to the cytoplasm in the presence of FBS.
  • Inhibition of Akt led to nuclear accumulation of FOXO1 and enhanced apoptosis in NSCLC cells.
  • Positive FOXO1 staining in early-stage NSCLC tumors without nodal involvement showed a significant correlation with favorable prognosis.

Conclusions:

  • FOXO1 nuclear localization is associated with favorable outcomes in NSCLC.
  • Akt inhibition promotes FOXO1 nuclear translocation and induces apoptosis, highlighting a potential therapeutic target.
  • FOXO1 expression serves as a favorable prognostic biomarker in NSCLC.